PSMA-binding radioligands (e.g. 177Lu-PSMA-617 and 225Ac-PSMA-617) have shown promise for treatment of metastatic prostate cancer (Jones et al. 2020). The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.